{
  "question_stem": {
    "en": "The antiviral activity of a guanosine derivative is tested by examining cells infected with different viruses for characteristic abnormal changes in cell morphology due to the viruses. These structural changes in host cells are known as cytopathic effects (CPE). In the presence of significant antiviral activity, CPE will be inhibited. The following results are obtained from the study:\n\n|                               | CPE without antiviral agent | CPE with antiviral agent |\n| :---------------------------- | :-------------------------- | :----------------------- |\n| Herpes simplex virus 1         | +++                         | none                     |\n| Herpes simplex virus 2         | +++                         | none                     |\n| Epstein-Barr virus            | +++                         | ++                       |\n| Varicella zoster virus        | +++                         | none                     |\n| Cytomegalovirus               | +++                         | ++                       |",
    "zh": "通过检查感染不同病毒的细胞，观察由于病毒引起的细胞形态特征性异常变化，来测试鸟苷衍生物的抗病毒活性。宿主细胞的这些结构变化被称为细胞病变效应（CPE）。在存在显著抗病毒活性时，CPE将被抑制。从研究中获得以下结果：\n\n|                               | 未使用抗病毒药物的CPE | 使用抗病毒药物的CPE |\n| :---------------------------- | :-------------------------- | :----------------------- |\n| 单纯疱疹病毒1型               | +++                         | 无                       |\n| 单纯疱疹病毒2型               | +++                         | 无                       |\n| EB病毒                      | +++                         | ++                       |\n| 水痘-带状疱疹病毒             | +++                         | 无                       |\n| 巨细胞病毒                   | +++                         | ++                       |"
  },
  "question": {
    "en": "A difference in which of the following best explains the variation in susceptibility of the various viruses to this specific antiviral agent?",
    "zh": "以下哪一项差异最能解释各种病毒对这种特定抗病毒剂的易感性差异？"
  },
  "options": {
    "A": {
      "en": "DNA polymerase structure",
      "zh": "DNA聚合酶结构"
    },
    "B": {
      "en": "Drug degradation rate",
      "zh": "药物降解速率"
    },
    "C": {
      "en": "Viral phosphorylating enzyme",
      "zh": "病毒磷酸化酶"
    },
    "D": {
      "en": "Viral capsid protein composition",
      "zh": "病毒衣壳蛋白组成"
    },
    "E": {
      "en": "Viral protease activity",
      "zh": "病毒蛋白酶活性"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "The drug described in this study demonstrates significant antiviral activity (thereby reducing cytopathic effects) against herpes simplex virus type 1 (HSV 1), HSV 2, and varicella zoster virus (VZV) but has weak activity against Epstein-Barr virus (EBV) and cytomegalovirus (CMV). This agent is most likely acyclovir, a guanosine analog. Once acyclovir enters the HSV-infected host cell, it is phosphorylated to acyclovir monophosphate, principally via a viral-encoded thymidine kinase. This is the rate-limiting step in acyclovir activation. Acyclovir monophosphate is then phosphorylated by cellular enzymes into the active triphosphate form, which then impairs viral DNA polymerase-mediated replication.\n\nEBV and CMV do not produce the same thymidine kinase as HSV and VZV. As a result, EBV- or CMV-infected cells cannot easily convert acyclovir into its pharmacologically active form. At very high intracellular concentrations of acyclovir, a small amount of the drug is activated by unidentified cellular phosphorylating enzymes, which may explain the partial susceptibility of EBV and CMV to high acyclovir doses.\n\n(Choices A, B, and E) Mutations in viral DNA polymerase can lead to acyclovir resistance, but differences in thymidine kinase are the best explanation for the observed results. Drug degradation rate and viral protease activity are not responsible for differences in viral susceptibility to acyclovir.\n\n(Choice D) Thymidine kinase is an enzyme produced in infected cells, but it is not present in the viral capsid.\n\nEducational objective:\nMonophosphorylation of acyclovir by a viral thymidine kinase is the first (and rate-limiting) step in conversion of acyclovir to its active triphosphate form. Acyclovir and related drugs (eg, famciclovir, valaciclovir) are more effective against herpes simplex virus and varicella zoster virus than cytomegalovirus and Epstein-Barr virus.",
    "zh": "本研究中描述的药物对单纯疱疹病毒1型（HSV 1）、HSV 2和水痘-带状疱疹病毒（VZV）表现出显著的抗病毒活性（从而降低细胞病变效应），但对EB病毒（EBV）和巨细胞病毒（CMV）的活性较弱。这种药物很可能是阿昔洛韦，一种鸟苷类似物。阿昔洛韦进入HSV感染的宿主细胞后，主要通过病毒编码的胸苷激酶被磷酸化为阿昔洛韦单磷酸。这是阿昔洛韦激活的限速步骤。然后，阿昔洛韦单磷酸被细胞酶磷酸化成活性三磷酸形式，从而损害病毒DNA聚合酶介导的复制。\n\nEBV和CMV不产生与HSV和VZV相同的胸苷激酶。因此，EBV或CMV感染的细胞不易将阿昔洛韦转化为其药理活性形式。在高胞内阿昔洛韦浓度下，少量药物被未知的细胞磷酸化酶激活，这可能解释了EBV和CMV对高剂量阿昔洛韦的部分易感性。\n\n（选项A、B和E）病毒DNA聚合酶的突变可导致阿昔洛韦耐药，但胸苷激酶的差异是解释观察结果的最佳方法。药物降解速率和病毒蛋白酶活性不是病毒对阿昔洛韦易感性差异的原因。\n\n（选项D）胸苷激酶是在受感染细胞中产生的酶，但它不存在于病毒衣壳中。\n\n教育目标：\n阿昔洛韦通过病毒胸苷激酶单磷酸化是阿昔洛韦转化为其活性三磷酸形式的第一步（也是限速步骤）。阿昔洛韦和相关药物（例如，泛昔洛韦、伐昔洛韦）对单纯疱疹病毒和水痘-带状疱疹病毒的疗效优于对巨细胞病毒和EB病毒的疗效。"
  },
  "summary": {
    "en": "This question tests knowledge of antiviral mechanisms, specifically the role of viral phosphorylating enzymes in the activation of acyclovir and its differential efficacy against various herpesviruses. It highlights the importance of viral thymidine kinase in the initial phosphorylation step required for acyclovir's antiviral activity.\n\nTo solve this question, focus on the differences in viral susceptibility to acyclovir as presented in the table. Recognize that acyclovir requires phosphorylation by viral enzymes to become active, and variations in these enzymes explain the observed differences in antiviral activity.",
    "zh": "此问题测试对抗病毒机制的知识，特别是病毒磷酸化酶在阿昔洛韦激活中的作用及其对各种疱疹病毒的不同疗效。它强调了病毒胸苷激酶在阿昔洛韦抗病毒活性所需的初始磷酸化步骤中的重要性。\n\n要解决这个问题，请关注表中呈现的病毒对阿昔洛韦的易感性差异。认识到阿昔洛韦需要病毒酶磷酸化才能激活，并且这些酶的变异解释了观察到的抗病毒活性的差异。"
  },
  "tags": "Acyclovir; Viral phosphorylating enzyme; Thymidine kinase; Herpes simplex virus; Varicella zoster virus; Epstein-Barr virus; Cytomegalovirus; Antiviral agents; Viral replication; Infectious diseases",
  "category": "Micro",
  "question_id": "1645",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Micro 23\\1645",
  "extracted_at": "2025-11-05T15:01:34.866885",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:09:58.058541",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}